CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 203 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01827319
NCT01827319N/ACompleted

A Multi-Center Single Arm Observational Registry of the Cardiogenesis Holmium: YAG Laser System Transmyocardial Revascularization for Angina Reduction

Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.·observational·Posted Apr 9, 2013·Updated Aug 15, 2016

In Brief

An observational study for Class IV Angina. Completed, enrolled 203 participants across 24 sites.

Detailed Summary

The objectives of the registry are as follows: * Track "real world" performance outcomes and physician experience using the Cardiogenesis Laser System; * Further define the disease characteristics of the population being treated; * Examine transmyocardial revascularization (TMR) usage characteristics and 30-day outcomes; * Further assess the 30-day postoperative risk factors for adverse events. To limit the potential for bias, all patients eligible for TMR treatment who meet the Inclusion and Exclusion Criteria are to be offered the opportunity to enroll in the study at participating centers.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsClass IV Angina
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 9, 2013
Enrollment StartMay 1, 2013
Primary CompletionApr 1, 2015
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.2 years ago